24th Conference on Retroviruses and Opportunistic Infections (CROI 2017), 13-16 February 2017, Seattle
This issue of HTB includes further reports from the 24th Conference on Retroviruses and Opportunistic Infections (CROI 2017) held in Seattle from 13-16 February 2017.
CROI is one of the leading scientific HIV meetings and the exciting news is that there was much to report.
The conference also provides free access to the conference materials online, including comprehensive webcasts of all oral presentations, available immediately after each session.
The programme for the meeting and abstract books can be downloaded as PDF files.
The searchable abstracts database links directly to PDF files for most posters.
New CROI reports for this issue of HTB South include:
- Pre-ART drug resistance in rural South Africa but limited clinical impact with good adherence
- Increased risk of IRIS with integrase inhibitors reported in two studies
- Dolutegravir exposure increases when fixed dose combination tablets are crushed
- Dose reduction potential of nanoparticle ARV formulations confirmed in humans
- Breakthrough for treating XDR-TB and ameliorating TB-IRIS
- Significant interaction between once-weekly isoniazid/rifapentine and daily dolutegravir: study stopped due to toxicity
- Adverse pregnancy outcomes and risk factors in the PROMISE trial
- PrEP in pregnancy does not increase poor birth outcomes
- Pharmacokinetics, safety and efficacy of dolutegravir in very young children
- Raltegravir pharmacokinetic targets met in high-risk HIV-exposed infants
- Tenofovir alafenamide exposure modestly higher in children than adults
- VRC01 in HIV-exposed newborns: first results support monthly injections for those at risk through breastfeeding
- World Health Organisation paediatric dosing tool
- Paediatric HIV: CROI 2017